DexCom (TICKER: DXCM) Benchmark And Performance Data

there are 11 of samples in the benchmark for DexCom in year 2022 in 2022. The total inventory for DexCom was $9,000,000.00 in 2013. The total inventory for DexCom was $70,700,000.00 in 2018. The total inventory for DexCom was $7,400,000.00 in 2012. The total inventory for DexCom was $45,400,000.00 in 2016. The total inventory for DexCom was $45,200,000.00 in 2017. The total inventory for DexCom was $357,300,000.00 in 2021. The total inventory for DexCom was $35,200,000.00 in 2015. The total inventory for DexCom was $234,700,000.00 in 2020. The total inventory for DexCom was $16,000,000.00 in 2014. The total inventory for DexCom was $119,800,000.00 in 2019. The sales, general, and administrative (SGA) for DexCom was $84,200,000.00 in 2013. The sales, general, and administrative (SGA) for DexCom was $806,800,000.00 in 2021. The sales, general, and administrative (SGA) for DexCom was $64,000,000.00 in 2012. The sales, general, and administrative (SGA) for DexCom was $620,700,000.00 in 2020. The sales, general, and administrative (SGA) for DexCom was $515,700,000.00 in 2019. The sales, general, and administrative (SGA) for DexCom was $432,800,000.00 in 2018. The sales, general, and administrative (SGA) for DexCom was $349,200,000.00 in 2017. The sales, general, and administrative (SGA) for DexCom was $286,200,000.00 in 2016. The sales, general, and administrative (SGA) for DexCom was $198,000,000.00 in 2015. The sales, general, and administrative (SGA) for DexCom was $128,400,000.00 in 2014. The sales, general, and administrative (SGA) for DexCom was $$1,000,000,000 in 2022. The revenue volatility for DexCom was 34.16% in 2022. The market capitalization for DexCom was $52,990,734,000.00 in 2013. The market capitalization for DexCom was $52,084,150,000.00 in 2014. The market capitalization for DexCom was $50,187,960,000.00 in 2015. The market capitalization for DexCom was $49,617,711,000.00 in 2020. The market capitalization for DexCom was $45,031,368,000.00 in 2019. The market capitalization for DexCom was $43,739,870,075.00 in 2018. The market capitalization for DexCom was $41,290,900,000.00 in 2012. The market capitalization for DexCom was $36,188,438,566.00 in 2021. The market capitalization for DexCom was $31,104,548,000.00 in 2017. The market capitalization for DexCom was $29,260,478,000.00 in 2016. The market capitalization for DexCom was $$48,606,000,000 in 2022. The gross revenue for DexCom was $99,900,000.00 in 2012. The gross revenue for DexCom was $718,500,000.00 in 2017. The gross revenue for DexCom was $573,300,000.00 in 2016. The gross revenue for DexCom was $402,000,000.00 in 2015. The gross revenue for DexCom was $259,200,000.00 in 2014. The gross revenue for DexCom was $2,448,500,000.00 in 2021. The gross revenue for DexCom was $160,000,000.00 in 2013. The gross revenue for DexCom was $1,926,700,000.00 in 2020. The gross revenue for DexCom was $1,476,000,000.00 in 2019. The gross revenue for DexCom was $1,031,600,000.00 in 2018. The gross revenue for DexCom was $$2,910,000,000 in 2022. The gross margin for DexCom was $13.44% in 2022. The days sales outstanding for DexCom was 77 days in 2022. The days payable outstanding for DexCom was 76 days in 2022. The days of inventory for DexCom was $118 in 2022. The cost of goods sold (COGS) for DexCom was 35.28% in 2022. The cost of goods sold (COGS) for DexCom was $82,900,000.00 in 2014. The cost of goods sold (COGS) for DexCom was $768,000,000.00 in 2021. The cost of goods sold (COGS) for DexCom was $646,600,000.00 in 2020. The cost of goods sold (COGS) for DexCom was $59,900,000.00 in 2013. The cost of goods sold (COGS) for DexCom was $544,500,000.00 in 2019. The cost of goods sold (COGS) for DexCom was $53,300,000.00 in 2012. The cost of goods sold (COGS) for DexCom was $367,700,000.00 in 2018. The cost of goods sold (COGS) for DexCom was $226,400,000.00 in 2017. The cost of goods sold (COGS) for DexCom was $194,900,000.00 in 2016. The cost of goods sold (COGS) for DexCom was $123,600,000.00 in 2015. The cost of goods sold (COGS) for DexCom was $$1,027,000,000 in 2022. The cash to cash cycle time for DexCom was 119 in 2022. The annual percentage growth rate of DexCom was -0.19% in 2022. DexCom in its benchmark peer group, had rank 9 for sales growth in 2022. DexCom in its benchmark peer group, had rank 9 for gross revenue in 2022. DexCom in its benchmark peer group, had rank 5 for cost of goods sold as a percent of revenue in 2022. DexCom in its benchmark peer group, had rank 5 days for days of inventory in 2022. DexCom in its benchmark peer group, had rank 4 for cash to cash cycle time in 2022. DexCom in its benchmark peer group, had rank 10 days for days sales outstanding in 2022. DexCom headquarters region is West. DexCom has ticker symbol DXCM. DexCom has the following profile: DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.. DexCom has primary indstury Medical Devices. DexCom had a $$825,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. DexCom had Abbott Laboratories, and QuidelOrtho, and Zimmer Biomet, and Edwards Lifesciences, and Bio-Rad Laboratories, and Boston Scientific, and Align Technology, and Stryker, and AdaptHealth, and Bruker, and DexCom benchmark peer companies for its SIC code in 2022. DexCom had 7,600 number of employees in 2022. DexCom had 44 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. DexCom had 3.73% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. DexCom had 3.72% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. DexCom had 20.84% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. DexCom had 17 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. DexCom had 10 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. DexCom had 0.14% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. DexCom can reduce overall cost by $$249,000,000 by improving both COGS and SGA to next benchmark tier in 2022. DexCom can reduce inventory with practices including SKU Reduction in 2022. DexCom can reduce inventory with practices including Reduce Manufacturing Latency in 2022. DexCom can reduce inventory with practices including Forecast Accuracy in 2022. DexCom can reduce inventory with practices including Demand Shaping in 2022. DexCom can reduce days sales outstanding with practices including in 2022. DexCom can increase sales revenue by $$825,000,000 improving sales performance to next benchmark tier in 2022. DexCom can increase revenue growth by $$4,000,000 by improving growth performance to next benchmark tier in 2022. DexCom can increase overall revenue by $$829,000,000 by improving both growth and sales performance to next benchmark tier in 2022. DexCom can increase days payables outstanding with practices including in 2022. DexCom can increase days payables outstanding by $0 days by increasing days payables outstanding to next benchmark tier in 2022. DexCom can improve total financial performance by $$1,293,000,000 by improving revenue, costs, and working capital in 2022. DexCom can decrease overall working capital by $$215,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. DexCom can decrease inventory days by $80,000,000 days by reducing inventory days to next benchmark tier in 2022. DexCom can decrease days sales outstanding by $136,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. DexCom can accelerate revenue growth practices including Revenue-optimized Planning in 2022. DexCom can accelerate revenue growth practices including Pricing Optimization in 2022. DexCom can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 94 days was the measured superior or top ten performance level for days of inventory in DexCom's peer group in 2022. 9.89% was the measured superior or top ten performance level for sales volatility in DexCom's peer group in 2022. 75 days was the measured superior or top ten performance level for cash to cash cycle time in DexCom's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in DexCom's peer group in 2022. 53 days was the measured advantage or top third performance level for days sales outstanding in DexCom's peer group in 2022. 44 days was the measured superior or top ten performance level for days sales outstanding in DexCom's peer group in 2022. 37.24% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in DexCom's peer group in 2022. 31.56% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in DexCom's peer group in 2022. 30.00% was the measured superior or top ten performance level for gross margin in DexCom's peer group in 2022. 29.10% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in DexCom's peer group in 2022. 159 days was the measured parity or middle performance level for days of inventory in DexCom's peer group in 2022. 138 days was the measured parity or middle performance level for cash to cash cycle time in DexCom's peer group in 2022. 13.32% was the measured parity or middle performance level for sales volatility in DexCom's peer group in 2022. 119 days was the measured advantage or top third performance level for cash to cash cycle time in DexCom's peer group in 2022. 11.40% was the measured advantage or top third performance level for sales volatility in DexCom's peer group in 2022. 108 days was the measured advantage or top third performance level for days of inventory in DexCom's peer group in 2022. 0.04% was the measured superior or top ten performance level for sales growth in DexCom's peer group in 2022. -0.05% was the measured parity or middle performance level for sales growth in DexCom's peer group in 2022. -0.02% was the measured advantage or top third performance level for sales growth in DexCom's peer group in 2022. $18.02% was the measured advantage or top third performance level for gross margin in DexCom's peer group in 2022. $17.18% was the measured parity or middle performance level for gross margin in DexCom's peer group in 2022. $$6,940,000,000 was the measured advantage or top third performance level for gross revenue in DexCom's peer group. $$3,735,000,000 was the measured parity or middle performance level for gross revenue in DexCom's peer group in 2022. $$18,449,000,000 was the measured superior or top ten performance level for gross revenue in DexCom's peer group in 2022.